{"product_id":"kinase-inhibitor-drugs-isbn-9780470278291","title":"Kinase Inhibitor Drugs","description":"\u003cb\u003eA comprehensive resource on case studies of marketed kinase drugs and promising drug trials\u003c\/b\u003e  \u003cp\u003eSince the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development.\u003c\/p\u003e \u003cp\u003eIn one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. \u003ci\u003eKinase Inhibitor Drugs\u003c\/i\u003e includes:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eCase studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eCurrent thinking on kinase structure, biochemistry, and signal transduction pathways\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eInformation on state-of-the-art technologies and tools such as structure-based and fragment-based drug discovery\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eA lineup of clinical-phase growth factor receptor inhibitors\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eInhibitors of cell cycle kinases\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe discovery of allosteric inhibitors of MEK kinase\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eInformation on pharmacogenomics and its application to kinase inhibitor clinical development\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e  \u003cb\u003ePREFACE.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eCONTRIBUTORS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I GROWTH FACTOR INHIBITORS: VEGFR2, ERBB2, AND OTHER KINASE.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis (\u003ci\u003eConnie L. Sun, James G. Christensen, and Gerald McMahon\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e2 Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibitor (\u003ci\u003eKaren Lackey and G. Stuart Cockerill\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e3 Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor (\u003ci\u003ePhilip A. Harris and Jeffrey A. Stafford\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e4 Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor (\u003ci\u003eMichael Michaelides and Daniel H. Albert\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e5 Discovery of Motesanib (\u003ci\u003eAndrew S. Tasker and Vinod F. Patel\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e6 Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor (\u003ci\u003eRajeev S. Bhide and Joseph Fargnoli\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e7 S tructure-Based Design and Characterization of Axitinib (\u003ci\u003eRobert S. Kania\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II GROWTH FACTOR INHIBITORS: MEK INHIBITORS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8 Road to PD0325901 and Beyond: The MEK Inhibitor Quest (\u003ci\u003eJudith S. Sebolt-Leopold and Alexander J. Bridges\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e9 Discovery of Allosteric MEK Inhibitors (\u003ci\u003eEli Wallace and James F. Blake\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III CELL CYCLE KINASE INHIBITORS: AURORA KINASE AND PLK INHIBITORS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Discovery of MK-0457 (VX-680) (\u003ci\u003eJulian M. C. Golec\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e11 Discovery of PHA-739358 (\u003ci\u003eDaniele Fancelli and Jürgen Moll\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e12 Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity (\u003ci\u003eKevin M. Foote and Andrew A. Mortlock\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e13 Case Study of Aurora-A Inhibitor MLN8054 (\u003ci\u003eChristopher F. Claiborne and Mark G. Manfredi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e14 Discovery of GSK461364: A Polo-like Kinase 1 Inhibitor for the Treatment of  Cancer (\u003ci\u003eKevin W. Kuntz and Kyle A. Emmitte\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV RELATED SPECIAL TOPICS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15 Pharmacogenomics of Dasatinib (Sprycel) (\u003ci\u003eFei Huang and Edwin A. Clark\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e16 Practical Use of Computational Chemistry in Kinase Drug Discovery (\u003ci\u003eJames M. Veal\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e17 Approaches to Kinase Homology Modeling: Successes and Considerations for the Structural Kinome (\u003ci\u003eVictoria A. Feher and J. David Lawson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e18 Fragment-Based Drug Discovery of Kinase Inhibitors (\u003ci\u003eDaniel A. Erlanson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e19 Protein Kinase Structural Biology: Methods and Strategies for Targeted Drug Discovery (\u003ci\u003eClifford D. Mol, Kengo Okada, and David J. Hosfield\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eINDEX.\u003c\/b\u003e\u003c\/p\u003e  \"In conclusion, I strongly recommend this book to anyone who is interested and new to the field of kinase inhibitors. Indeed, I believe this book should not merely sit on the shelves of kinase experts, but should be used frequently for reference.\" (\u003ci\u003eChemMedChem\u003c\/i\u003e, 2010)\u003cbr\u003e \u003cbr\u003e  \"Delivers what the title promises: a comprehensive treatment of drugs that inhibit kinases. ... Will be interesting to any chemist or biologist desiring a behind-the-scenes look at modern strategies of drug discovery and their practical applications to some challenging targets.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e, April 2010)  \u003cb\u003eRongshi Li, PhD\u003c\/b\u003e, is an Associate Professor in the Drug Discovery Department at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.  \u003cp\u003e\u003cb\u003eJeffrey A. Stafford, PhD\u003c\/b\u003e, has led drug discovery research at GlaxoSmithKline, Syrrx, and Takeda. He is a co-inventor of the tyrosine kinase inhibitor, pazopanib (Armala).\u003c\/p\u003e  \u003cb\u003eA comprehensive resource on case studies of marketed kinase drugs and promising drug trials\u003c\/b\u003e  \u003cp\u003eSince the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development.\u003c\/p\u003e \u003cp\u003eIn one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. \u003ci\u003eKinase Inhibitor Drugs\u003c\/i\u003e includes:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eCase studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eCurrent thinking on kinase structure, biochemistry, and signal transduction pathways\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eInformation on state-of-the-art technologies and tools such as structure-based and fragment-based drug discovery\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eA lineup of clinical-phase growth factor receptor inhibitors\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eInhibitors of cell cycle kinases\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe discovery of allosteric inhibitors of MEK kinase\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eInformation on pharmacogenomics and its application to kinase inhibitor clinical development\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989498675429,"sku":"NP9780470278291","price":179.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470278291.jpg?v=1761784347","url":"https:\/\/k12savings.com\/es\/products\/kinase-inhibitor-drugs-isbn-9780470278291","provider":"K12savings","version":"1.0","type":"link"}